Paper · 2015 · Open access

A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.

Daniel R Jones

Europe PMC (PubMed Central), 3(14), 189 · Published 1 August 2015 · DOI 10.3978/j.issn.2305-5839.2015.07.01

Open full textView at the publisherCite this paper

In brief

“A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.” is a 2015 paper by Daniel R Jones, published in Europe PMC (PubMed Central). OpenAlex counts 15 citations as of 19 November 2026. It is open access: the full text is free to read at Europe PMC (PubMed Central).

Citations
15
Most cited in
2025 (5)
Field-weighted impact
0.38
References
34
Authors
1

Abstract

One of the pivotal factors in the health and maintenance of dense bone is the coordinated activity of osteoblasts and osteoclasts. Research scientists are developing an enormous knowledge base about the signaling that occurs between these two cell types with the goal of understanding the bone microenvironment under normal as well as resorptive disease states. This knowledge base has already led to the development of successful therapies for osteoporosis. The monoclonal antibody to receptor activator of nuclear factor-κB ligand (RANKL), known as Prolia ® (denosumab), is a recent example. RANKL is a cytokine expressed on the surface of the osteoblast in response to bone resorption cues like 1α,25-dihydroxyvitamin D3, parathyroid hormone (PTH), prostaglandin E 2 (PGE 2 ), and interleukin 11 (IL-11). A second cytokine, macrophage colony-stimulating factor (M-CSF), is released by the osteoblast on a continual basis with both cytokines promoting differentiation of osteoclast precursors. The osteoclast precursors express receptors for the two cytokines, c-Fms (M-CSF receptor) and RANK (RANKL receptor). Another ligand for c-Fms is IL-34, expressed primarily by splenic red pulp, which appears to act in concert with M-CSF and RANKL. Osteoblasts express a third factor which is a soluble tumor necrosis factor (TNF) receptor family member, osteoprotegrin (OPG), that serves as a “decoy” receptor for RANKL and thereby blocks RANKL-RANK binding to inhibit osteoclastogenesis. A construct of OPG in which the heparin-binding and death homology domains are removed and the remaining peptide is fused to the F c domain of the human immunoglobulin G1 (IgG1) is used for experimental therapeutic purposes. The resulting fusion protein construct is called OPG-F c , and it neutralizes RANKL. In a study of ovariectomized (OVX) rats, the combined use of OPG-F c and alendronate (a commonly used bisphosphonate) significantly increased the mechanical strength properties of femurs and lumbar vertebrae bodies compared to treatment with either OPG-F c or alendronate alone.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Jones, D. R. (2015). A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling. Europe PMC (PubMed Central), 3(14), 189. https://doi.org/10.3978/j.issn.2305-5839.2015.07.01

MLA 9

Jones, Daniel R. “A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.” Europe PMC (PubMed Central), vol. 3, no. 14, 2015, p. 189. https://doi.org/10.3978/j.issn.2305-5839.2015.07.01.

Chicago

Jones, Daniel R. 2015. “A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.” Europe PMC (PubMed Central) 3 (14): 189. https://doi.org/10.3978/j.issn.2305-5839.2015.07.01.

Harvard

Jones, D. R. (2015) ‘A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.’, Europe PMC (PubMed Central), 3(14), p. 189. doi:10.3978/j.issn.2305-5839.2015.07.01.

IEEE

D. R. Jones, “A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.,” Europe PMC (PubMed Central), vol. 3, no. 14, p. 189, 2015, doi: 10.3978/j.issn.2305-5839.2015.07.01.

BibTeX

@article{jones2015potential,
  title     = {{A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.}},
  author    = {Jones, Daniel R},
  journal   = {Europe PMC (PubMed Central)},
  year      = {2015},
  volume    = {3},
  number    = {14},
  pages     = {189},
  doi       = {10.3978/j.issn.2305-5839.2015.07.01},
  url       = {https://doi.org/10.3978/j.issn.2305-5839.2015.07.01}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201711
201833
202122
202211
202322
202411
202555

Its field-weighted citation impact is 0.38: it has been cited 0.38 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases

  • osteoporosis
  • Fas ligand
  • Fas pathway
  • RANKL
  • osteoprotegrin
  • osteoclastogenesis
  • denosumab
  • alendronate

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Jones, D. R. (2015). A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling. Europe PMC (PubMed Central), 3(14), 189. https://doi.org/10.3978/j.issn.2305-5839.2015.07.01

How many times has this paper been cited?

15 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Europe PMC (PubMed Central): sign in and open the full text from this page.

Who wrote this paper?

Daniel R Jones.

What is the DOI of this paper?

10.3978/j.issn.2305-5839.2015.07.01, permanently at https://doi.org/10.3978/j.issn.2305-5839.2015.07.01. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.